Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details specific share purchases made on October 4, 2013, at a price of 1,558.50 pence per Ordinary Share. These transactions resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA). The changes in shareholdings are as follows:
- Sir Andrew Witty: +70 shares
- Lady C Witty (Connected Person): +7 shares
- Mr S M Bicknell: +93 shares
- Mr D S Redfern: -18 shares
- Mrs V A Whyte: +15 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Share transactions occurred on October 4, 2013, at 1,558.50 pence per share.
- Transactions were driven by dividend re-investment within ISAs, not open market purchases.
- Net changes in holdings were minor, ranging from -18 to +93 shares per individual.
- The filing was signed by Simon Bicknell, Company Secretary, on October 7, 2013.